These findings demonstrate that FTO inhibition is sufficient to inhibit ccRCC tumor progression in cell line–derived xenografts and PDX and its effect on tumor growth can be enhanced with PARP inhibition. The gene discussed is FTO; the disease is nonpapillary renal cell carcinoma.